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Abstract: Anti-tumor necrosis factor alpha (TNF-α) therapy has re-defined our treatment 
paradigms in managing patients with Crohn’s disease (CD) and ulcerative colitis. Although 
the ACCENT studies showed proven efficacy in the induction and maintenance of disease 
remission  in  adult  patients  with  moderate  to  severe  CD,  the  pediatric  experience  was 
instrumental in bringing forth the notion of “top-down” therapy to improve overall clinical 
response  while  reducing  the  risk  of  complications  resulting  from  long-standing  active 
disease. Infliximab has proven efficacy in the induction and maintenance of disease remission 
in  children  and  adolescents  with  CD.  In  an  open-labeled  study  of  112  pediatric  patients 
with moderate to severe CD, 58% achieved clinical remission on induction of infliximab   
(5 mg/kg) therapy. Among those patients who achieved disease remission, 56% maintained 
disease remission on maintenance (5 mg/kg every 8 weeks) therapy. Longitudinal follow-up 
studies have also shown that responsiveness to infliximab therapy also correlates well with 
reduced rates of hospitalization, and surgery for complication of long-standing active disease, 
including stricture and fistulae formation. Moreover, these children have also been shown 
to improve overall growth while maintaining an effective disease remission. The pediatric 
experience has been instructive in suggesting that the early introduction of anti-TNF-α therapy 
may perhaps alter the natural history of CD in children, an observation that has stimulated a 
great deal of interest among gastroenterologists who care for adult patients with CD.
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Introduction
Crohn’s disease (CD) and ulcerative colitis are chronic inflammatory intestinal 
disorders affecting 1.7 million people in North America.1 Recent studies have shown 
an increasing incidence of CD in children, and an overall prevalence of 10% to 25% 
of all patients with inflammatory bowel disease (IBD).2,3 CD is characterized by patchy 
transmural inflammation involving any segment of the gastrointestinal tract from 
the mouth to the anus. Patients will typically show recurrent clinical exacerbations 
marked by symptoms of abdominal pain, diarrhea, and rectal bleeding, alternating with 
episodes of quiescent disease. Children often manifest constitutional signs of weight 
loss, growth failure and pubertal delay that may in part be secondary to extensive 
proximal small bowel disease of increased severity. Moreover, pediatric CD is often 
associated with extra intestinal manifestations, including arthritis, episcleritis, uveitis 
and erythema nodosum.1
Although the principal goal of therapy is to induce and maintain an effective disease 
remission, the intestinal mucosa will often show ongoing inflammation that contributes Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
58
Parashette et al
to frequent relapses and less than favorable maintenance of 
clinical remission. Since CD may progress from intestinal 
inflammation to strictures and penetrating disease, including 
fistulas and abscess formation, mucosal healing has become 
a primary treatment objective. Since delayed puberty and 
growth failure is seen in 15% to 40% of pediatric patients 
with CD,4 achieving normal growth and development also 
represents an important end-point to therapy. The ultimate 
goal is to achieve and sustain an effective disease remission 
that avoids complications associated with long-standing and 
unremitting disease. To achieve this clinical objective is of 
paramount importance in order to improve patient quality 
of life, and avoid psychological complications, including 
anxiety, and depression. Given the myriad of potential 
therapies available to treat patients with CD, it has become 
increasingly important to select those medications with the 
most favorable benefit risk ratio that will minimize the overall 
need for corticosteroids (Figure 1).
Non-biological therapy
Enteral nutrition has proven efficacy in inducing disease 
remission in children with active CD,5 as well as preventing 
disease relapse in 60% to 75% of patients within a year.6,7 
Although enteral nutrition is effective in inducing disease 
remission and in reversing micronutrient deficiencies, these 
treatment formulas are unpalatable and often require naso-
gastric or gastrostomy tube placement. Typically, adolescent 
patients are non-adherent to the prolonged implementation 
of nutritional therapy. They often object to the placement of 
these feeding tubes or the exclusivity of enteral nutritional 
therapy during periods of quiescent disease.5–7
Thomsen and coworkers showed in a double blind 
multicenter study of 182 adults with CD that mesalamine was 
able to induce remission in 45%, 42% and 36% of patients 
with mild to moderate disease at the end of 8 weeks, 12 weeks 
and 16 weeks, respectively.8 However, de Franchis and 
coworkers showed that once patients achieved disease 
remission on mesalamine, less than 50% of patients were able 
to sustain disease remission after one year of maintenance 
therapy.9
Although studies have shown that corticosteroids are 
effective in inducing remission in patients with active CD,10 
not all patients respond favorably. And among those patients 
that respond to induction corticosteroids, 40% to 68% of 
patients will relapse within a year, while up to 36% of patients 
will develop corticosteroid dependency.11–14 This observation 
is also underscored by the detrimental impact of long-term 
corticosteroid use on patient growth and development.
Immunosuppressant drugs, including methotrexate, aza-
thioprine (AZA, and 6-mercaptopurine (6-MP) are all effec-
tive in maintain disease remission in 40% to 65% of patients 
with corticosteroid-dependent moderate to severe CD.15–18
Biological therapy
In comparison, the biological agents used in CD include: 
the anti-tumor necrosis factor alpha (TNF-α) agents 
  infliximab, adalimumab and certolizumab pegol (Figure 2) 
and   anti-adhesion molecule drugs. All of these biological 
agents have been shown to be effective in children with CD. 
Herein, our focus will be on the role of infliximab in treating 
pediatric CD.
TNF-α
Over the last several years, our understanding of the 
pathogenesis of CD has improved remarkably with the 
development of several animal models. Indeed, the pro-
inflammatory cytokine TNF-α is known to play an important 
role in CD,19 and has led to the development of several 
novel treatment strategies, including infliximab. TNF-α 
can transmit signals between immune cells leading to 
inflammation, thrombosis and fibrinolysis. Various stimuli, 
including bacterial endotoxin, radiation and viral antigens 
can bring on the release of secretory TNF-α from monocytes, 
macrophages and T-cell lymphocytes. As a potent pro-
inflammatory cytokine, TNF-α must be firmly regulated; 
and failure to do so, allows for an unmediated inflammatory 
response.20 In patients with CD, TNF-α is highly localized to 
the intestinal mucosa and lumen. Indeed, high concentrations 
have been measured in the lamina propria of the bowel of 
patients with CD21 and increased concentration of TNF has 
also been found in the stool of children with CD.22 At the 
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level of the mucosa, TNF-α recruits circulating inflammatory 
cells to the intestinal tissue, inducing tissue edema, coagula-
tion activation through thrombin activation and granuloma 
formation. The migration of neutrophils is further facilitated 
through the increased expression of adhesion molecules and 
IL-8 by endothelial cells. TNF-α is pivotal in the formation 
of granulomas, one of the histological hallmarks of CD. 
Through its up-regulation of monocyte chemo-attractant 
protein-1, monocytes are recruited into the site of gra-
mulomatous inflammation. CD4 T-cell lymphocytes are 
the probable source for TNF-α production, as well as other 
cytokines involved in the so-called TH1 response, including 
interferon-α at the site of granulomas.
Infliximab
Infliximab is a chimeric IgG-1 monoclonal antibody with 
a high specificity for TNF-α. It induces apoptosis of TNF-
producing cells, and promotes antibody dependent and 
complement dependent cytotoxicity.23–25 It has been shown 
to decrease histologic and endoscopic disease activity 
and in inducing and maintaining remission in patients 
with active CD. ACCENT I was a multicenter random-
ized double-blind international trial studying retreatment 
and remission maintenance in adult patients with CD 
treated with infliximab. Patients in this study were divided 
into 3 groups: patients given a single 5 mg/kg infusion, 
patients given 5 mg/kg every 8 weeks, and patients given 
10 mg/kg every 8 weeks for maintenance of remission. 
After 54 weeks, the initial clinical response was maintained 
in only 17% of patients in the single dose group compared 
to 43% of patients maintained on 5 mg/kg every 8 weeks 
and 53% of patients maintained on 10 mg/kg every 8 weeks. 
In addition, successful steroid-tapering was seen in only 
9% of patients in the single dose group compared to 28% 
in the 5 mg/kg every 8 weeks group, and 32% of patients 
in the 10 mg/kg every 8 weeks group.26
It has been the practice in many institutions, including 
our own to initiate maintenance anti-TNF-α therapy in 
patients that have shown clear refractoriness to either long-
term 6-MP or AZA therapy. All of the studies, including 
ACCENT, CHARM and PRECISE have not shown any 
potential role of combining anti-TNF-α with anti-metabolite 
therapy. Moreover, the increasing concern of hepatic T-cell 
lymphoma has led many physicians to consider discontinu-
ing either 6-MP or AZA with the introduction of biological 
therapy.27 Although all anti-TNFα therapies have antigenic 
properties, those patients on infliximab therapy are most vul-
nerable. The concurrent use of immunosuppressive therapy 
has in the past been shown by Rutgeerts and coworkers 
to maintain a favorable clinical response to maintenance 
infliximab therapy, presumably due to the prevention of 
human anti-chimeric antibody (HACA) antibody formation. 
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In that study, 75% (12/16) of patients on concurrent 6-MP 
maintained a favorable clinical response, compared to 50% 
(9/18) on no concurrent immunosuppressive therapy.28 In 
the ACCENT 1 study, only 18% of the patients on neither 
concurrent prednisone nor immunosuppressive drug therapy 
developed HACA, compared to just 10% of patients on 
concurrent azathioprine or methotrexate therapy.26 The 
therapeutic benefit of concurrent immunosuppressive therapy 
is generally considered marginal and is felt to not outweigh 
the associated increased risk of hepatic T-cell lymphomas, a 
malignancy that is universally lethal in the pediatric patient 
population.27 Moreover, both adalimumab and certolizumab 
have proven efficacy in salvaging those patients who develop 
either a partial responsiveness or intolerance to infliximab 
therapy.28 As a result, the purported benefit is not felt to 
outweigh the increased risk for malignancy.
Other drug safety issues with infliximab include the devel-
opment of anti-neutrophil antibodies and anti-double stranded 
DNA in 34% and 56% of patients on maintenance infliximab 
therapy, respectively. Furthermore, the long-term risk in devel-
oping systemic lupus is unknown, and may have an increased 
bearing on the African-American population. Other noteworthy 
long-term safety issues include the risk of super-infection (32%) 
and the risk of tuberculosis.11
Adalimumab
The immunogenicity of infliximab has led to the development 
of other less immunogenic TNF inhibitory agents, including 
adalimumab and certolizumab. Adalimumab (fully human 
anti-TNF) has recently received approval for the treatment 
of active CD. Several studies have shown adalimimab to be 
superior to placebo for inducing and maintaining remission. 
It has also been shown to spare corticosteroids and salvage 
those patients with CD recalcitrant to infliximab therapy with 
an excellent safety profile. Unlike infliximab, adalimumab 
is prescribed as a subcutaneous injection every 2 weeks as a 
maintenance therapy.28,29
Infliximab use in children
Studies evaluating the safety and efficacy of infliximab 
in children were first reported in several non-randomized 
studies.30–34 These initial studies showed that the response and 
remission rates (both partial and complete) were far superior 
compared to conventional therapy. Interestingly, its efficacy 
in children appeared to be higher than in adult.31,32
In a multicenter, open-label, dose-blinded trial (n = 21), 
Baldassano and coworkers demonstrated the efficacy and 
safety of a single infusion of infliximab in the treatment of 
pediatric CD. During the 12-week duration of the study, 
100% achieved a clinical response and 48% achieved clinical 
remission, with significant improvements in the pediatric CD 
activity index (PCDAI), modified CDAI, erythrocyte sedi-
mentation rate, and other outcome variables of interest. There 
were no infusion reactions in any of the patients and it was 
suggested that infliximab may be safe and effective as short-
term therapy of medically refractory moderate to severe CD.35 
A prospective study published by Cezard and coworkers also 
explored the efficacy and toxicity of infliximab in children 
with severe CD. Twenty-one children (median age 15, range 
13 to 17) were treated with infliximab with an induction 
sequence of 5 mg/kg at 0, 15, and 45 days. Nineteen children 
were in complete remission (defined as Harvey-Bradshaw 
index (HBI) ,4) on day 45. 14/21 patients had stopped taking 
steroids at 3 months, and all had stopped parenteral nutrition. 
All perianal fistulas (n = 12) were also closed by day 90 and 
the drug appeared to be well tolerated.36
Much evidence at present comes from retrospective 
analysis of children treated with infliximab, often as a 
rescue medication. In a retrospective study in children and 
adolescents with either corticosteroid dependent or resistant 
CD, patients were randomized to receive 1 to 3 infusions of 
infliximab (5 mg/kg/dose) over a 12-week period. The mean 
daily prednisone dosages decreased significantly in all the 
patients (P , 0.01) studied. A significant initial improvement 
(as assessed by a significant decline in PCDAI value) was 
noted in all subjects (P , 0.0001). Interestingly, over the 
subsequent 8-week period, 8 of 19 treated subjects had wors-
ening of symptoms.37 Lamireau and coworkers described yet 
another retrospective study in 88 children and adolescents 
(median age: 14, range: 3.3 to 17.9) treated with infliximab 
for active disease (66%) and/or fistulas (42%) that were 
refractory to corticosteroids (70%), and/or other immuno-
suppressive (82%) agents, and/or parenteral nutrition (20%). 
Patients received a median of 4 (1 to 17) infusions of 5 mg/kg 
of infliximab during a median time period of 4 months (1 to 
17 months). From day 0 to day 90, the Harvey-Bradshaw 
score decreased from 7.5 to 2.8 (P , 0.001), with a significant 
decrease in both C-reactive protein and ESR (P , 0.001). At 
day 90 after the first infusion of infliximab, 49% of patients 
had symptom improvement, 29% were in remission; 53% of 
patients could be weaned off of corticosteroids and 92% off 
of parenteral nutrition.38 The authors in both these studies 
concluded that treatment with infliximab was well tolerated 
and effective in most children and adolescents with CD 
refractory to conventional immunosuppressive therapy. No 
serious events were noted in any of these studies.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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The Food and Drug Administration (FDA) approval for 
the use of infliximab therapy in pediatric CD was based on 
the results of the much publicized REACH clinical study, 
a randomized, multicenter, open-label study to evaluate 
the safety and efficacy of anti-TNF-α antibody in pediatric 
subjects with moderate to severe CD. A total of 112 pedi-
atric patients (ages 6 to 17 years) with moderate to severe 
CD who took part in this study received infliximab at 
5 mg/kg at week 0, 2 and 6. Patients who showed symptom 
improvement, or response, were then randomized to 2 groups 
and received infliximab every 8 or 12 weeks for almost 1 year. 
A concurrent immunomodulator was also required. At week 
10, 88% patients showed response (defined as decrease from 
baseline in the PCDAI score $15 points; total score #30) 
and 58% patients achieved clinical remission (defined as 
PCDAI score #10 points). At week 54, 63% and 56% 
patients receiving infliximab every 8 weeks were in clinical 
response and clinical remission, respectively, compared with 
33% and 23% patients receiving treatment every 12 weeks 
(P = 0.002 and P , 0.001, respectively). The data from this 
important prospective trial thus suggested that infliximab 
is not only highly effective in inducing clinical response 
and remission but also in maintenance of remission, more 
so with an 8-week dosing compared with every 12-week 
dosing.39 The same research consortium also found infliximab 
to be an effective therapy in children with perianal disease, 
including patients with perianal fistula,40 and in prolonging 
the withdrawal of corticosteroids over a 3-year follow-up 
period.41 Similar observations have also been made in an 
European study in children with CD. In that study, children 
on an on-demand treatment schedule were more-likely to 
experience a relapse (92%) when compared to patients on 
2-month infusion schedule (23%).42
immunogenicity
HACA is the common side effect of infliximab infusion. 
The antibody is as a result of murine component of chimeric 
infliximab. However, adalimumab a fully human anti-TNF-α 
drug also has similar side-effects. In the REACH study, 
2.9% (3 patients) developed HACA when compared to 35% 
on other trials.39,43–45 This could be explained by patients in 
the REACH study receiving concurrent immunosuppres-
sive medication. Seventy-seven percent of patients in the 
REACH had inconclusive HACA results. HACA causes 
infusion reactions (acute and delayed), shortened response 
and also loss of response. Risk factors for development of 
HACA are single and episodic infusion, female gender, long 
gap between first and second infusion, and previous infusion 
reaction. Studies suggest that it can me minimized by giving 
maintained therapy, a concomitant immunosuppressive 
agent, and corticosteroid.44,45
Acute infusion reaction occurs in 11% to 8% patients 
and at 2.5% to 5.3% per infusion depending on the dosing 
method and concomitant treatment.39,46–48 Patients develop 
pruritus, chest pain, nausea, headache, and flushing within 
24 hours. Antihistamines and/or corticosteroids do not 
prevent the infusion reaction. However, infusion reaction can 
be controlled by slow infusion, along with administration of 
antihistamine and corticosteroids. It is our general practice to 
pre-medicate those patients susceptible to infliximab-induced 
infusion reactions with hydrocortisone therapy.48
Delayed infusion reaction is very rare (0.7% to 3%). 
Patients presents after 4 to 9 days with back pain, myalgia, 
arthralgia, and skin rash.46,47 It is seen after the second or 
third infusion dose and usually responds to corticosteroid 
therapy.
Infliximab therapies often induce formation of anti 
nuclear antibody and anti double standard antibody.49 
However these antibodies are not of any clinical significance 
as studies suggest that no pediatric patients have developed 
drug-induced systemic lupus or organ damage.
infections
Infliximab causes decreased levels of polymorph nuclear 
cells and T-cell lymphocytes specifically at mucosal site. 
This results in increased risk of infectious with bacteria, 
virus and fungi. Active infection is a contraindication for 
infliximab use. Also, live vaccines are contraindicated as 
there is an increase risk of serious infection. Every patient 
has to undergo a screening test for tuberculosis, as multiple 
studies suggest reactivation of latent tuberculosis.50,51
The risk of infection is 3.8% to 8% and the upper 
respiratory tract is commonly affected.26,52 In the REACH 
study, the incidence rate of upper respiratory tract infection 
was 35.8% and 32.0% in patients receiving infliximab every 
8 weeks and every 12 weeks, respectively.39 Overall infection 
rate was high (73.6%) among the first group patients than 
the later group (38.0%). But serious infection occurred at 
the same rate in both the groups (5.7% to 8%). In a study 
of adult patients with CD, Colombel and coworkers treated 
500 patients with infliximab, 41 (8.2%) of whom developed 
infection. Among these 41 patients, 15 had serious infection 
(2 fatal sepsis, 8 pneumonia, 1 severe viral gastroenteritis, 
2 abdominal abscess, 1 arm cellulitis, 1 histoplasmosis).53 
Other studies also suggest the occurrence of Listeria 
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herpes zoster.45,54 One report also suggests reactivation of 
hepatitis B in 3 patients diagnosed with chronic hepatitis B 
on treatment with infliximab.55
Malignancy
In a prospective study of 20 patients, 28% developed 
reactivation of Epstein-Barr virus (EBV). However, EBV 
PCR level returned to normal after 6 months of discontinuing 
infliximab.56 In a study of 6290 adult patients on maintenance 
infliximab therapy, there was no increased risk of malignancy 
in the infliximab group compared to patients on conventional 
therapy.57 In a multi-center matched-pair trial, the incidence 
rate of malignancy was 2.2% (9 patients) in the CD group 
and 1.7% (7 patients) in the non-CD group after a follow-
up of 4.5 years.58 Meena and coworkers first reported a case 
of hepatosplenic T-cell lymphoma in a 17-year-old female 
CD patient treated with infliximab and 6-MP.27 Nine more 
cases of hepatic T-cell lymphoma have been reported in IBD 
patients treated with infliximab and 6-MP/AZA.59 However 
there is no case report of an IBD patient developing hepatic 
T-cell lymphoma on infliximab alone.
Summary
The arsenal of biological therapies is increasing. A large 
multi-centered pediatric study is now investigating the use 
of adalimumab in children with CD. Furthermore, the FDA 
approval of certolizumab, a novel pegylated anti-TNF therapy, 
is expected soon. The pediatrician will soon be faced with 
the dilemma of which medications to use, in either the more 
traditional step-up or top-down approach. Indeed, there is a 
growing tendency to consider biological drugs in lieu of more 
traditional therapies, as discussed above. While genotype–
phenotype correlations may allow clinicians to predict certain 
more aggressive forms of CD, future studies are still needed 
to provide an evidenced-based approach to drug therapy.
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